The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Category: Infectious Disease & AMR

Researchers discover new hiding place for antibiotic resistance
Infectious Disease & AMR

Researchers discover new hiding place for antibiotic resistance

DEC 20, 2021
Engineering the Microbiome to Treat Skin Diseases
Biotech Showcase

Engineering the Microbiome to Treat Skin Diseases

NOV 16, 2021
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
Clinical & Manufacturing

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

NOV 12, 2021
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
Finance

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

NOV 10, 2021
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Clinical & Manufacturing

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

OCT 5, 2021
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection
Editor's Choice

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection

SEP 30, 2021
BiomX Inc. Announces $15 Million Registered Direct Offering
Finance

BiomX Inc. Announces $15 Million Registered Direct Offering

JUL 27, 2021
Seres Therapeutics Announces FDA Clearance of IND for Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and GvHD
Finance

Seres Therapeutics Announces FDA Clearance of IND for Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and GvHD

JUN 4, 2021
Global microbiome study discovers thousands of new species, maps urban antimicrobial resistance and reveals new drug candidates
Infectious Disease & AMR

Global microbiome study discovers thousands of new species, maps urban antimicrobial resistance and reveals new drug candidates

JUN 3, 2021
Ben-Gurion University researchers developing probiotic yogurt-based drugs
Biotics and Supplements

Ben-Gurion University researchers developing probiotic yogurt-based drugs

MAY 12, 2021
Of mice and men and their different tolerance to pathogens
Infectious Disease & AMR

Of mice and men and their different tolerance to pathogens

MAR 23, 2021